{"analyses":[{"ciLowerLimit":"0.37","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.93","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0217","paramType":"Hazard Ratio (HR)","paramValue":"0.59","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.87","upperLimit":"45.67","value":"29.80"},{"groupId":"OG001","lowerLimit":"13.83","upperLimit":"27.70","value":"17.41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"description":"OS is the time from randomization to the date of death from any cause. The survival time for participants who had not died was censored at the last known alive date. OS was censored at the date of randomization for subjects who were randomized but had no follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Elotuzumab + Pomalidomide + Dexamethasone","id":"OG000","title":"E-Pd Cohort"},{"description":"Pomalidomide + Dexamethasone","id":"OG001","title":"Pd Cohort"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to death (up to approximately 52 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}